Albany, NY -- (SBWire) -- 12/18/2017 --The global market for non-small cell lung cancer therapeutics is expected to be worth US$15.1 bn by 2023. On the basis of geography, Asia Pacific will emerge as the most lucrative regional market on account of growing awareness about cancer and increasing number of government projects supporting lung cancer treatment. On the basis of drugs, the angiogenesis inhibitor segment is estimated to lead on account of the efficacious nature of this drug and rise in the adoption of targeted therapy in the U.S., Japan, and European markets, says TMR. The angiogenesis inhibitor segment is predicted to be worth US$ 2,020.4 mn by 2023.
Report overview @ https://www.transparencymarketresearch.com/non-small-cell-lung-cancer-market.html
The global Non-Small Cell Lung Cancer Therapeutics Market is segmented on the basis of Drug Class,Pipeline.
On the basis of geography, the global market for NSCLC therapeutics has been segmented into Europe, Asia Pacific, North America, and the Rest of the World. Thanks to the presence of a state-of-art healthcare infrastructure, North America has emerged as the leading contributor to this market. With favorable insurance and reimbursement scenario, researchers expect this regional market to remain dominant in the forthcoming years.
The global market for non-small cell lung cancer therapeutics market can be segmented on the basis of drugs into EGFR inhibitor, angiogenesis inhibitor, microtubule stabilizer, kinase inhibitor, folate antimetabolites, and PD-1/PD-L1 inhibitor. At present angiogenesis inhibitor, also known as anti-angiogenics that thwart formation of new blood vessels, dominates the market. Going forward too, it is likely to retain its leading position because of the strong demand for this efficacious, targeted therapy in the crucial Europe, Japan, and the U.S. markets. Avastin, a type of angiogenesis inhibitor, is predicted to see maximum uptake. Exhibiting a CAGR of 1.8% from 2015 to 2023, the angiogenesis inhibitor segment is predicted to attain a market value of US$ 2,020.4 mn by 2023.
The folate antimetabolites segment trails the angiogenesis inhibitor segment in the global non-small cell lung cancer therapeutics market. The EGFR inhibitor and microtubule stabilizer segments come in third and fourth positions in terms of market share. The PD-1/PD-L1 inhibitor will likely outpace all other segments vis-à-vis growth in the upcoming years due to the effectiveness of the treatment, which has been corroborated by clinical data that shows double survival rate. Unveiling of new targeted therapies with more surveillance rate could, however, hobble the growth in the market.
Request A Sample Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=504
Summary of Table of Content
1. Preface
2. Executive Summary
3. Non-Small Cell Lung Cancer Market Overview
4. Market Segmentation – By Drug
5. Pipeline Analysis
6. Market Segmentation – By Geography
7. Recommendations
8. Company Profiles
Get Full Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=504
Global Non-Small Cell Lung Cancer Therapeutics Market: Segmental Highlights and Table of Content (2015–2023)
Global Non-Small Cell Lung Cancer Therapeutics Market: Manufacturers Take Holistic Approach to Expand Therapeutics Pipeline